Cerestat: Completed enrollment in a 120-patient Phase II dose response study in the U.S. and Europe. Data from these patients and a nearly completed dose rangin

Cambridge Neuroscience Inc. (CNSI), Cambridge, Mass. Product: Cerestat, NMDA ion channel blocker Indication: Stroke Status: Completed enrollment in a 120-patient Phase II dose response study in the U....